Navigation Links
Mast Therapeutics Announces Positive Data In Model Of Heart Failure
Date:1/6/2014

160;

The Company is enrolling subjects in EPIC, a pivotal phase 3 study of MST-188 in sickle cell disease.  In early 2014, the Company plans to initiate a phase 2, clinical proof of concept study in acute limb ischemia that will evaluate whether MST-188 improves the effectiveness of existing thrombolytic agents.  The Company also is evaluating development options in heart failure.  More information can be found on the Company's web site at www.masttherapeutics.com.  (Twitter: @MastThera)

Mast Therapeutics™ and the corporate logo are trademarks of Mast Therapeutics, Inc.

Forward Looking Statements
Mast Therapeutics cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that are based on the Company's current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements regarding MST-188's prospects in heart failure, the potential market in that indication, and the Company's development plans for MST-188 in heart failure and in acute limb ischemia, including the timing of initiation of any clinical studies.  Among the factors that could cause or contribute to material differences between the Company's actual results and the expectations indicated by the forward-looking statements are risks and uncertainties that include, but are not limited to: delays in the commencement or completion of clinical studies, including as a result of difficulties in obtaining regulatory agency agreement on clinical development plans or clinical study design, opening trial sites, enrolling study subjects, manufacturing sufficient quantities of clinical trial material, being subject to a "clinical hold," and/or suspension or termination of a clinical study, including due to patient safety concerns or lack of funding; the
'/>"/>

SOURCE Mast Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... The quantum dot market report analyzes the ecosystem of the ... product includes medical devices, display, and others. The others segment ... storage, QD laser, and transistor. The application segment covers the ... The report also provides the geographic view for major regions ... Europe , Asia-Pacific (APAC), and ...
(Date:9/2/2015)... , Sept. 2, 2015 About Duchenne ... X-linked disease, which generally affects the male population. ... weakness. The disease is caused due to mutations ... lack of production of dystrophin (a protein essential ... lack of dystrophin weakens muscle function, causes loss ...
(Date:9/2/2015)... Sept. 2, 2015  Array BioPharma Inc. (Nasdaq: ... Executive Officer, Ron Squarer , will present ... Boston.  The public is welcome to participate in ... BioPharma website.Event: Wells Fargo Securities Healthcare ConferencePresenter: Ron ... 2015Time:  , 10:20 a.m. Eastern Time Webcast: ...
Breaking Medicine Technology:Quantum Dot Market by Product , Material, Application, and Geography- Forecast up to 2020 2Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 2Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 3
... May 25, 2011 Each month, millions of women suffer ... of the all-new AZO PMS™ -- the only ... women can now get relief from PMS with a fast ... PMS refers to a wide range of physical ...
... May 25, 2011 Graymark Healthcare, Inc. (NASDAQ: ... services and an innovator in comprehensive care for obstructive sleep ... 1-for-4 reverse stock split, which will be effective after the ... The 1-for-4 reverse stock split will automatically convert all shares ...
Cached Medicine Technology:New AZO PMS™ Delivers Fast, Natural Relief from Symptoms Associated with Premenstrual Syndrome 2New AZO PMS™ Delivers Fast, Natural Relief from Symptoms Associated with Premenstrual Syndrome 3Graymark Announces 1-for-4 Reverse Stock Split 2
(Date:9/2/2015)... ... September 03, 2015 , ... The Aspen Clinic (TAC), located ... geared towards kick-starting and inspiring wellness in the Roaring Fork Valley and beyond. , ... a whole mind-body approach to fitness - we are much more than a gym. ...
(Date:9/2/2015)... ... September 03, 2015 , ... Each year, the editors ... public servants, activists, corporate executives, entrepreneurs, health care professionals, and others have had ... led the magazine to tap the National League for Nursing’s outspoken CEO, ...
(Date:9/2/2015)... ... 02, 2015 , ... Healthegy, a leading producer of conferences, ... will deliver keynote presentations at the upcoming Digital Healthcare Innovation Summit ( http://www.digitalhealthcaresummit.com/ ... , Larry Renfro, CEO of Optum, will deliver the morning address. In his ...
(Date:9/2/2015)... , ... September 02, 2015 , ... ... gift from the Abraham and Mildred Goldstein Charitable Trust to establish the Abraham ... the gift comes six months after WCHN recruited nationally known gynecologic oncologist Thomas ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... efficacy endpoint data collection, cloud analytics and workflow solutions today announced the ... enables pharmaceutical researchers to participate in interactive programs in which ERT scientists ...
Breaking Medicine News(10 mins):Health News:TAC Introduces New Retreats for Fall Fitness 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 3Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 2Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 3Health News:Western Connecticut Health Network Receives $1 Million Gift to Establish Ovarian Cancer Research Endowment 2Health News:Western Connecticut Health Network Receives $1 Million Gift to Establish Ovarian Cancer Research Endowment 3Health News:ERT Announces Web Seminar Series on Optimizing Trial Data Collection & Gaining Real-Time Data Insights 2Health News:ERT Announces Web Seminar Series on Optimizing Trial Data Collection & Gaining Real-Time Data Insights 3
... News) -- New research finds that adults who suffered from ... fever -- are nine times more likely to have allergic ... are based on about 1,400 adults who have been followed ... Study. The study participants were assessed in 1968, when they ...
... TUESDAY, April 19 (HealthDay News) -- About 1 in ... -- meaning the virus becomes resistant to multiple drugs ... European study shows. That drug failure rate is ... maintaining viral load suppression in young patients who begin ...
... Amanda Gardner HealthDay Reporter , TUESDAY, April 19 ... for the diagnosis of Alzheimer,s disease could double the number ... guidelines, issued Tuesday by the Alzheimer,s Association and the U.S. ... the last recommendations, which have been in use since 1984. ...
... TUESDAY, April 19 (HealthDay News) -- People who have ... hospital than they did almost two decades ago, but discharges ... a result, Iowa researchers report. Using Medicare data on ... 2008, the researchers found that hospital stays are now averaging ...
... available in French . , Montreal April ... age, yet the reasons for this increasing forgetfulness have not ... older individuals have reduced learning and memory because their minds ... Published in The Quarterly Journal of Experimental Psychology, ...
... Goodwin HealthDay Reporter , TUESDAY, April 19 (HealthDay ... either had or were going to get all of the ... doctor,s advice on immunizations, two new surveys find. Pediatricians ... years of hype about a supposed autism/MMR (measles, mumps, rubella) ...
Cached Medicine News:Health News:Kids' Eczema, Hay Fever Linked to Allergic Asthma Later 2Health News:Children With HIV at Higher Risk of Drug Resistance 2Health News: Alzheimer's Cases Could Double With New Guidelines: Expert 2Health News: Alzheimer's Cases Could Double With New Guidelines: Expert 3Health News:Shorter Hospital Stays, More Readmissions After Hip Replacements 2Health News:Shorter Hospital Stays, More Readmissions After Hip Replacements 3Health News:Spring-cleaning the mind? 2Health News:Most Parents Vaccinate Kids, Trust Docs' Advice on Shots 2Health News:Most Parents Vaccinate Kids, Trust Docs' Advice on Shots 3
Inquire...
Inquire...
... EDTA K2 or EDTA K3 tubes. ... therefore blocks the coagulation cascade. Erythrocytes, ... anticoagulated blood sample are stable for ... are for the examination of whole ...
... the most powerful, productive ... and rich in features, ... a comprehensive authoring environment ... custom interactive multimedia content ...
Medicine Products: